Cancer Progress, in its 30th year, has an outstanding reputation as the premier annual oncology conference that affords a unique dialogue among 200 key opinion leaders in the cancer field. We bring together top cancer researchers, clinical investigators and senior executives from the pharmaceutical, biotechnology, payer, regulatory, development, diagnostic, data and investment arenas. Pivotal topics, frank discussions, vigorous debate, lively audience participation and networking combine to make this a highly impactful conference.

Register with discount code: MYBIO for $300 off

We look forward to seeing you in May!

Plenaries

  • Has the Time Come for Chemo-& Immuno-Prevention: Nixing the Nabobs of Negativity
  • Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New
  • Basket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech
  • IO Session I: Combination Failures & Futures: Much Ado About What?
  • Payer/Access Panel
  • IO Session II: IO Targets and Platforms-Target Versus Modality-What Are the Keys to the Kingdom?
  • Gynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care
  • Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Different New?
  • Insights from Heme Malignancies: Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients
  • Oncology Innovation Powered by Investments and Competition from China

 

Keynote Speakers

Rachel Haurwitz, PhD
Chief Executive Officer and Founder
Caribou Biosciences, Inc.
Gregory C. Simon
President
Biden Cancer Initiative
Burt Zweigenhaft
Managing Partner
Upstream Partners Inc.
Register-Button2.png